
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is a surgical robotics company with a strong focus on advancing patient care. The company has a promising product pipeline with the AquaBeam and HYDROS robotic systems, and a potential market opportunity in treating BPH and prostate cancer. Though there may be near-term challenges with sales force restructuring and reimbursement dynamics, strong capital placements and enthusiasm for the technology suggest potential for long-term growth and success. Financially, the company has demonstrated strong domestic capital placements and high average selling prices, indicating potential for revenue growth and profitability in the future. The company's current stock price may not fully reflect its potential success in the market, making it a potential investment opportunity.
Bears say
PROCEPT BioRobotics is facing challenges with its utilization rates and potential competition in the market, leading to lowered procedure forecasts and a potential impact on revenue growth in the coming years. This, coupled with management's overly aggressive outlook for procedure growth and potential reimbursement changes for Aquablation, could hinder the stock's performance. Additionally, there may be some concerns about the sales initiatives and their potential impact on utilization rates in the long term.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares